WO2001085202A2 - Electroporation for introduction of molecules into cells - Google Patents
Electroporation for introduction of molecules into cells Download PDFInfo
- Publication number
- WO2001085202A2 WO2001085202A2 PCT/GB2001/001970 GB0101970W WO0185202A2 WO 2001085202 A2 WO2001085202 A2 WO 2001085202A2 GB 0101970 W GB0101970 W GB 0101970W WO 0185202 A2 WO0185202 A2 WO 0185202A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- poiynucleotide
- muscle
- dna
- mammal
- Prior art date
Links
- 238000004520 electroporation Methods 0.000 title description 79
- 108091007433 antigens Proteins 0.000 claims abstract description 139
- 102000036639 antigens Human genes 0.000 claims abstract description 139
- 239000000427 antigen Substances 0.000 claims abstract description 129
- 239000007924 injection Substances 0.000 claims abstract description 113
- 238000002347 injection Methods 0.000 claims abstract description 113
- 238000000034 method Methods 0.000 claims abstract description 108
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 56
- 241000124008 Mammalia Species 0.000 claims abstract description 43
- 230000004936 stimulating effect Effects 0.000 claims abstract description 13
- 230000004700 cellular uptake Effects 0.000 claims abstract description 5
- 230000000899 immune system response Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 239000013612 plasmid Substances 0.000 claims description 41
- 230000000638 stimulation Effects 0.000 claims description 39
- 230000028993 immune response Effects 0.000 claims description 35
- 210000000663 muscle cell Anatomy 0.000 claims description 20
- 230000003444 anaesthetic effect Effects 0.000 claims description 18
- 230000024932 T cell mediated immunity Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000000890 antigenic effect Effects 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000028996 humoral immune response Effects 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 abstract description 4
- 102000040430 polynucleotide Human genes 0.000 abstract description 4
- 239000002157 polynucleotide Substances 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 103
- 210000003205 muscle Anatomy 0.000 description 88
- 241000699670 Mus sp. Species 0.000 description 64
- 241001465754 Metazoa Species 0.000 description 59
- 238000001890 transfection Methods 0.000 description 53
- 230000003053 immunization Effects 0.000 description 48
- 238000002649 immunization Methods 0.000 description 46
- 230000000694 effects Effects 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
- 239000002953 phosphate buffered saline Substances 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 26
- 108060001084 Luciferase Proteins 0.000 description 21
- 239000005089 Luciferase Substances 0.000 description 21
- 241000700159 Rattus Species 0.000 description 21
- 241000283707 Capra Species 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 14
- 101100131080 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) mpb70 gene Proteins 0.000 description 13
- 230000002068 genetic effect Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000005684 electric field Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 239000000835 fiber Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 101710128836 Large T antigen Proteins 0.000 description 8
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 229960005015 local anesthetics Drugs 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000043129 MHC class I family Human genes 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 210000002363 skeletal muscle cell Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- ACNUVXZPCIABEX-UHFFFAOYSA-N 3',6'-diaminospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(N)C=C1OC1=CC(N)=CC=C21 ACNUVXZPCIABEX-UHFFFAOYSA-N 0.000 description 4
- 101150079978 AGRN gene Proteins 0.000 description 4
- 108700019743 Agrin Proteins 0.000 description 4
- 102100040026 Agrin Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 101150052863 THY1 gene Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000001608 connective tissue cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000008348 humoral response Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101710087274 Endothelial lipase Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000993364 Homo sapiens Ciliary neurotrophic factor Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091061960 Naked DNA Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 102100035071 Vimentin Human genes 0.000 description 3
- 108010065472 Vimentin Proteins 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229920001308 poly(aminoacid) Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 229940124326 anaesthetic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940043517 specific immunoglobulins Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 108700028044 Ala(152)-Ala(155)-Asp(166)-His(167)- ciliary neurotrophic factor Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150030983 GEP gene Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101710110377 Immediate early protein IE1 Proteins 0.000 description 1
- 101710205424 Immediate-early protein 1 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000959590 Rattus norvegicus Agrin Proteins 0.000 description 1
- 101000941277 Rattus norvegicus Endothelial lipase Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 101710135389 Unconventional myosin-Ia Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- -1 pharmaceutical drugs Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36003—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of motor muscles, e.g. for walking assistance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
Definitions
- the present invention relates to a method for eliciting an immune response in an animal by injection of an antigen (e.g. a protein, peptide, nucleic acid or other molecule) into skeletal muscle, as well as to the use of an antigen for the preparation of an immunization composition for use in such a method.
- an antigen e.g. a protein, peptide, nucleic acid or other molecule
- antigens e.g. proteins, polypeptides, protein-epitope conjugates, and other molecules
- antigens e.g. proteins, polypeptides, protein-epitope conjugates, and other molecules
- a major obstacle facing the medical profession is how to safely deliver effective quantities of these antigens to patients to create the desired immune system response, e.g. for immunization or antibody production.
- most antigens are delivered orally or intravenously.
- Oral and intravenous delivery methods have several shortcomings.
- a large percent of orally or intravenously delivered agents are degraded by the body before arriving at the target organ or cells. Acids and enzymes in the stomach and intestine, for example, can break down many antigens, particularly proteins and oligo and polypeptides.
- intravenously delivered antigens are often sequestered by the liver or kidney before arriving at the desired cells.
- oral and intravenous delivery is non-specific. That is, the antigen is delivered to both target and non-target cells.
- Skeletal muscle is a promising candidate for antigen delivery.
- skeletal muscle constitutes over 50% of a human's body mass, most of which is easily accessible compared to other tissues and organs of the body.
- muscle is an ideal site for genetic immunization because it is easily accessible and proteins made in the muscle are secreted, thus eliciting an immune response.
- skeletal muscle cells are non-dividing. Therefore, skeletal muscle cells are capable of expressing a protein coded by a gene for a longer time period than would be expected of other cell types that are continually dividing. Because the protein is expressed for a longer time, fewer treatments would be necessary.
- bioactive agents into skeletal muscle, such as intramuscular injection.
- the invention provides a method of eliciting an immune system response in a mammal, e.g. a method of immunizing a mammal, which method comprises : injecting a first antigen, e.g.
- a poiynucleotide functionally encoding a second antigen into a second injection site in skeletal muscle in said mammal; positioning electrodes in said skeletal muscle such that current travelling between said electrodes passes through said first and/or second injection site; and electrically stimulating said skeletal muscle with an electrical current between said electrodes having a field strength in said skeletal muscle of from 10 to 300 V/cm, i.e. such that the mean potential gradient between the electrodes in the muscle is 10 to 300 V per cm, whereby to assist in cellular uptake of said first antigen and/or said poiynucleotide.
- the first and second injection sites may be the same or different, the first and second antigens may be the same or different, and injection of the first antigen and the poiynucleotide may be simultaneous or separate (locationally and/or temporally) . It is preferred however that the first and second injection sites are within the same muscle, it is also preferred that the first and second antigens share a common antigenic epitope, and it is further preferred that the first antigen is injected at least 24 hours prior to the poiynucleotide .
- poiynucleotide By functionally encoding it is meant that the poiynucleotide, optionally together with a further administered poiynucleotide, should enable a cell transfected therewith to express the second antigen.
- the poiynucleotide should possess (e.g. in the known manner) appropriate start and stop sequences and that it or a further poiynucleotide should functionally encode any enzymes required for expression of the second antigen that are not normally expressed by the mammalian cells.
- poiynucleotide is meant RNA or, more preferably, DNA, especially cDNA, optionally in the form of a plasmid.
- the invention provides a method of enhancing an immune response of a mammal comprising: injecting an antigen into a first injection site in the skeletal muscle of the mammal; positioning electrodes near the first injection site such that current travelling through the electrodes passes through the first injection site; electrically stimulating the muscle with a first electrical current having a field strength of from about 10 V/cm to about 233 V/cm; injecting a DNA molecule coding for the antigen into a second injection site in the skeletal muscle of the mammal ; positioning electrodes near the second injection site such that current travelling through the electrodes passes through the second injection site; and electrically stimulating the muscle with a second electrical current having a field strength of from about 10 V/cm to about 233 V/cm; wherein the DNA molecule is injected at a time of from about one week to about several years after the injection of the antigen.
- the invention provides the use of an antigen and/or a poiynucleotide functionally encoding an antigen for the manufacture of pharmaceutical compositions for use in a method of eliciting an immune response according to the invention.
- the invention provides a pharmaceutical composition for use in a method of eliciting an immune response according to the invention, said composition comprising an antigen and/or a poiynucleotide functionally encoding an antigen, together with a physiologically tolerable carrier or excipient .
- the invention also provides an antigen and/or a poiynucleotide functionally encoding an antigen for use in a method of eliciting an immune response according to the invention.
- the method of the invention comprises a method of immunizing a mammal with an antigen comprising: injecting the antigen into an injection site in the skeletal muscle of the mammal; positioning electrodes near the injection site such that current travelling through the electrodes passes through the injection site; and electrically stimulating the muscle with an electrical current having a field strength of from 10
- the method comprises a method of inducing a cellular immune response in a mammal comprising: injecting DNA encoding an antigen into an injection site in the skeletal muscle of the mammal; positioning electrodes near the injection site such that current travelling through the electrodes passes through the injection site; and electrically stimulating the muscle with an electrical current having a field strength of 10 V/cm to
- the method of the invention may be used to transfect not just skeletal muscle cells but a significant number of other cell types and hence that it is especially, and surprisingly, applicable for eliciting the T-cell and B-cell immune responses or for antigen delivery rather than simply for delivery of DNA.
- the immune response is potentiated by using a proteinaceous antigen and using a poiynucleotide functionally encoding an antigen possessing a common antigenic epitope.
- the invention thus provides the use of a poiynucleotide functionally encoding an antigen for the manufacture of a pharmaceutical composition for use in a method of treatment of a mammal to induce a cellular immune response, e.g.' an immune response, in the lymphatic system, which method comprises injecting said composition into an injection site in skeletal muscle of said mammal and electroporating cells around said injection site, e.g. using the techniques described herein.
- the invention thus provides the use of an antigen for the manufacture of a pharmaceutical composition for use in a method of treatment of a mammal to induce a humoral immune response, e.g. an immune response in the lymphatic system, which method comprises injecting said composition into an injection site in skeletal muscle of said mammal and electroporating cells around said injection site, e.g. using the techniques described herein.
- a humoral immune response e.g. an immune response in the lymphatic system
- the invention also provides a method of inducing a humoral immune response in a mammal comprising: injecting an antigen into an injection site in the skeletal muscle of the mammal; positioning electrodes near the injection site such that current travelling through the electrodes passes through the injection site; and electrically stimulating the muscle with an electrical current having a field strength of about 10 V/cm to about 233 V/cm.
- a pharmaceutical composition comprising a proteinaceous antigen and cell-free poiynucleotide (e.g. a plasmid) functionally encoding a protein antigen, optionally and preferably together with a physiologically acceptable carrier or excipient, preferably wherein said proteinaceous and protein antigens include at least one antigenically equivalent epitope.
- the invention provides a kit comprising: a first pharmaceutical composition comprising a proteinaceous antigen optionally and preferably together with a physiologically acceptable carrier or excipient; and a second pharmaceutical composition comprising cell-free poiynucleotide (e.g. a plasmid) functionally encoding a protein antigen, optionally and preferably together with a physiologically acceptable carrier or excipient, preferably wherein said proteinaceous and protein antigens have at least one antigenically equivalent epitope.
- a first pharmaceutical composition comprising a proteinaceous antigen optionally and preferably together with a physiologically acceptable carrier or excipient
- a second pharmaceutical composition comprising cell-free poiynucleotide (e.g. a plasmid) functionally encoding a protein antigen, optionally and preferably together with a physiologically acceptable carrier or excipient, preferably wherein said proteinaceous and protein antigens have at least one antigenically equivalent epitope.
- the invention provides the use of an antigenic substance and/or a poiynucleotide functionally encoding an antigen for the manufacture of a pharmaceutical composition for use in a method of introducing said antigenic substance and/or said poiynucleotide into non-muscle cells which comprises injecting said composition into an injection site in skeletal muscle of a mammal and electroporating cells around said injection site, e.g. using a technique as described herein.
- the method of the invention is thought to be similar to conventional electroporation in its transfection effect. Electroporation works on the principle that a cell acts as an electrical capacitor and is generally unable to pass current. Subjecting cells to a high-voltage electric field, therefore, creates transient permeable structures or micropores in the cell membrane. These pores are large enough to allow antigens, polyaminoacids, pharmaceutical drugs, polynucleotides, and other polar compounds to gain access to the interior of the cell. With time, the pores in the cell membrane close and the cell once again becomes impermeable .
- Transfection by the method of the present invention also allows effective immunisation using antigens, or the combination of antigens and polynucleotides encoding antigens (either simultaneously, or sequentially in any order) .
- transfection efficiency is observed if the muscle is electrically stimulated immediately, or shortly after the injection.
- the semipermeable quality of the tissue induced by the stimulation is reversible.
- it is dependent on current through the muscle; activity induced through the nerve does not affect transfection efficiency.
- the enhanced immune response provided by the current method occurs when the muscle is electrically stimulated immediately, or shortly after injection.
- the transfection method of the present invention can be used, for example, to transfect expression vectors for genetic immunization (e.g. DNA vaccines) .
- a local anaesthetic can be injected at the site of treatment prior to or in conjunction with the injection of the antigen or DNA.
- the antigen or DNA may be mixed with Marcain, a local anaesthetic, followed by electroporation. This is unexpected because Marcain is known to cause muscle cell death and so would be expected to greatly reduce transfection efficiency.
- the invention provides a method of delivering a molecule to the skeletal muscle of a mammal in vivo comprising: injecting a local anaesthetic into the skeletal muscle of the mammal; injecting a molecule into an injection site in the skeletal muscle; positioning electrodes near the injection site such that current travelling through the electrodes passes through the injection site; and electrically stimulating the muscle with an electrical current having a field strength of from 10 V/cm to 300 V/cm.
- this method comprises a method of delivering DNA molecule to the immune system of a mammal in vivo comprising: mixing a first solution comprising the DNA molecule with a second solution comprising a local anaesthetic to produce a DNA-anaesthetic mixture; injecting the DNA-anaesthetic mixture into an injection site in a skeletal muscle of the mammal; positioning electrodes near the injection site such that current travelling through the electrodes passes through the injection site; and electrically stimulating the muscle with an electrical current having a field strength of from 10 V/cm to 300 V/cm.
- Figure 1 graphically illustrates a method of delivering antigens and DNA into skeletal muscle according to the present invention.
- Figure 2 - is a graphical illustration of an electrical stimulation delivered according to the method of the present invention.
- Figure 3 - is an image of cells stained with anti- agrin polyclonal antibodies derived from a rabbit genetically immunized with an expression vector coding for rat agrin using the stimulation technique of the present invention
- Figure 4 - are graphs illustrating improved genetic immunization of mice and rats using the stimulation technique of the present invention versus naked DNA injection;
- Figure 5 - are graphs illustrating relative amounts of specific subtypes of antibody reactive with given antigens at four and eight weeks after immunization;
- Figure 6 - is a bar graph illustration of mean luciferase activity in lymph nodes of mice after transfection of muscle with Luc cDNA;
- Figure 7 - is a bar graph illustration of mean luciferase activity in lymph nodes of rats after transfection of muscle with Luc cDNA;
- Figure 8 - are graphs illustrating IgGl antibody levels in mice at 4 , 8, and 9 weeks after genetic immunization
- Figure 9 - are graphs illustrating IgG2a antibody levels in mice at 4, 8, and 9 weeks after genetic immunization
- Figure 10 are graphs illustrating IgG2b antibody levels in mice at 4 , 8, and 9 weeks after genetic immunization
- Figure 11 - is a bar graph illustrating luciferase activity in muscle cells 5 days after transfection with Luc plasmid DNA
- Figure 12 - is a bar graph illustrating mean luciferase activity in mouse muscles after a second immunization with 85B and luciferase cDNA (a low value indicates a strong cellular immune response and efficient killing of transfected cells) ;
- Figure 13 - are graphs illustrating antibody levels after protein immunization (a high level of IgGl indicates a humoral immune response) ;
- Figure 14 - are graphs illustrating antibody levels in mice eight weeks after genetic immunization with low electrical field strength;
- Figure 15 - are graphs illustrating the responses of T-cells from immunized animals to the indicated peptides;
- Figure 16 - are fluorescence micrographs showing (a) cells expressing green fluorescent protein after transfection by the method of the invention and (b) muscle-resident Adipocytes expressing the S-100 protein;
- Figure 17 - are fluorescence micrographs showing (a) cells expressing green fluorescent protein after transfection by the method of the invention and (b) muscle-resident connective tissue cells expressing the IgG protein thy-1; and
- Figure 18 - are fluorescence micrographs showing (a) cells expressing green fluorescent protein after transfection by the method of the invention and (b) muscle-resident connective tissue cells expressing the intracellular protein vimentin.
- Figure 19 - are graphs indicating the response of goats to transfection with DNA under sedation and local anesthetic, with and without electroporation (EP) .
- the present invention is directed to a novel method for administering an antigen, and optionally also a poiynucleotide encoding for an antigen.
- the method of the present invention involves passing an electrical current through the skeletal muscle tissue. Unlike previously described electroporation methods, however, the method of the present invention can be effected with a low field strength and thus causes much limited tissue damage. Other parameters such as the number of pulse trains, frequency, pulse number and pulse duration can be varied in order to regulate the amount of antigen or poiynucleotide delivered.
- the antigen administered in the method of the invention may be any antigenic molecule, it is preferably a polar species and more preferably it is peptidic, e.g.
- the antigen may be administered in order to stimulate an immune response so as to confer immunity to the antigen to the mammal or alternatively to provoke antibody production, e.g. for commercial use.
- the antigen is a protein or protein fragment, optionally an aglycosylic fragment.
- antigen "A” and a poiynucleotide encoding an antigen “B” are both administered, it is preferred that antigen “A” is peptidic and that antigen “B” should comprise a peptidic sequence having a high degree of homology with at least one epitope of antigen "A”, e.g. at least 80% homology, more preferably at least 90% homology (e.g. over a sequence of at least 20 amino acids, discounting deletions) .
- antigens "A” and “B” are identical, or antigen “A” should comprise the entire sequence (or at least 90% of the entire sequence) of antigen “B” or antigen “B” should comprise the entire sequence (or at least 90% of the entire sequence) of antigen “A” .
- the first antigen and the second antigen may conveniently be different surface proteins (or fragments /thereof) of the same viral, bacterial or fungal species.
- skeletal muscle is exposed and a predetermined amount of a molecule is injected into the muscle.
- the antigen or poiynucleotide is dissolved in 0.9% sodium chloride (NaCl) or another physiologically tolerable aqueous vehicle.
- NaCl sodium chloride
- the exact solvent is not critical to the invention.
- other materials such as sucrose are capable of increasing molecular uptake in skeletal muscle.
- Other substances may also be co- transfected with the molecule of interest for a variety of beneficial reasons. For example, P188 (Lee, et al .
- Electrodes are placed on the muscle, about 1-4 mm apart, near the area where the antigen or poiynucleotide molecule was injected.
- the exact position or design of the electrodes is not critical, however it is preferred that current pass through the muscle fibers perpendicular to their direction of orientation in the area of the injected molecule.
- the muscle is electroporated or stimulated.
- the stimulation is preferably delivered as a square bipolar pulse having a predetermined amplitude and duration.
- the voltages have ranged from approximately 0 to 50 volts; the pulse durations have ranged from 5 (is to 5 ms; the number of pulses have ranged from a single pulse to 30,000 pulses; and the pulse frequency within trains have ranged from 0.5 Hz to 1000 Hz.
- the conclusion from these results is that so long as the field strength is above 10 V/cm, preferably above 50 V/cm the other parameters may be varied depending on the experimental conditions desired. While no upper limit was detected, effective transfection efficiencies were observed with much higher field strengths .
- the field strength of the stimulation can be calculated using the formula:
- the field strength is between 163 V/cm - 43 V/cm (from 0.1 to 0.4 cm between electrodes, respectively) .
- the electrical stimulator used for the experiments was reported below manufactured by FHC (Brunswick, ME 04011) . Both Pulsar 6bp and the Pulsar 6bp-a/s stimulators have been used.
- the Pulsar 6bp-a/s delivers a maximal voltage of 150 V and a maximal current of 50 mA.
- the maximal voltage that can be delivered requires a resistance between the electrodes of greater than 3000 Ohms.
- the stimulators have been operated at constant voltage mode. Because of the low resistance in the muscle, the voltages have been lower in the Examples below. In all experiments the current has been maintained at 50mA.
- the nucleic acid is a DNA expression vector of the type well known in the art.
- an expression vector contains a promoter operably linked to a DNA molecule that codes for the protein of interest followed by a termination signal such as a polyadenylation signal.
- a termination signal such as a polyadenylation signal.
- Other elements required for bacterial growth and proper mammalian processing may be included, such as the ⁇ - lactamase coding region, an ft origin and ColE 1-derived plasmid replication origin. Similar constructs containing a DNA coding region of interest can be constructed by one skilled in the art.
- an immune response is generated by administration of a protein antigen and the corresponding cDNA, both by the method of the invention, either simultaneously or sequentially in either order.
- the period between administrations is typically 1 day-20 weeks (e.g. 2-16 weeks), particularly 4-8 weeks.
- the combination of DNA and antigen may also be used by administration of DNA by the method of the invention, either followed or preceded by injection of an antigen without electrical stimulation.
- an antigen may be, for example, a protein or a line or inactivated virus.
- the large T-antigen nuclear localization signal (a protein) is mixed with a plasmid containing the DNA coding region for an antigenic protein.
- the large T-antigen nuclear localization signal is a protein that binds DNA and facilitates its transport into the nucleus of a cell.
- large T-antigen nuclear localization signal has been shown to increase transfection efficiency. Using the method of the present invention, large T-antigen nuclear localization signal also increases the transfection efficiency of antigen-encoding DNA.
- the method of the present invention can particularly advantageously be used to drive the immune response of an animal in a specific direction.
- DNA encoding for an antigen was administered to a group of mice according to the method of the invention. After four and eight weeks, serum was collected from the mice and antibodies analyzed by ELISA. The mice had a high level of IgG2a antibodies that reacted with the antigen, indicating that a strong cellular immune response was induced.
- animals were immunized according to the method, increased numbers of CD8+ and CD4+ T-cells that secreted interferon gamma were measured with ELISPOT after stimulation with peptides specific for MIHC I and II binding. This demonstrates a strong cellular immune response as well as induction f Th-1 cells. When animals were given a boost injection in combination with a reporter gene a reduced expression of reporter gene (indicating a stronger cellular immune response) was observed in animals that had been immunized according to the present invention.
- Another example is to drive the immune response in the other direction with preferential stimulation of the humoral branch of the immune system.
- protein antigens were administered in accordance with the present invention, higher IgGl and IgG2b antibody titers could be detected.
- these protein-treated animals were given a boost injection of antigenic protein in combination with a reporter gene, increased expression of the reporter gene was observed.
- immunization may stimulate an immune reaction that is not efficient in killing muscle cells. This method may be useful for the treatment of various autoimmune diseases in which a strong cellular immune response causes or contributes to the disease.
- the present invention thus provides a method of controlled stimulation (and/or modulation) of the cellular and/or humoral branch of the mammalian immune system by administration of one or more doses of antigen and/or the corresponding DNA (especially cDNA) to muscles by injection and electrical stimulation, as described above. Where more than one administration is made, this may be of antigen and/or
- DNA DNA, simultaneously or sequentially in order to provide the desired combination of cellular and/or humoral response, as illustrated below.
- Such cells may include lymphocytes, macrophages, dendritic cells, etc.
- animals were intramuscularly injected with Luc cDNA. The muscles were electrically stimulated shortly after the injection. Animals were sacrificed at two and seven days, and their spleens and lymph nodes removed and analyzed for luciferase activity. As shown in Table 1 below and Figures 6 and 7, a large increase in luciferase activity in the lymph nodes and spleen was found.
- the invention therefore provides a method of transfecting non-muscle cells residing within skeletal muscles with nucleic acids (especially DNA and preferably cDNA) , antigens (particularly protein and other polyaminoacid antigens) and other molecules by the injection and electrical stimulation method as described above.
- nucleic acids especially DNA and preferably cDNA
- antigens particularly protein and other polyaminoacid antigens
- other molecules by the injection and electrical stimulation method as described above.
- a method is provided for inducing an immune response in a mammal by transfection of immune cells (such as lymphocytes, macrophages and/or dendritic cells) resident in skeletal muscles by inducing the uptake into such cells of DNA (preferably cDNA) , antigens
- transfection of muscle-resident non-muscle cells occurs to an extent at least as great and preferably greater than the extent of muscle cell transfection. This may be achieved, for example, by the use of low field strengths such as field strengths below 100 V/cm, particularly 5-100 V/cm and especially 5-25 V/cm.
- Local anaesthetics are frequently used in medical procedures to reduce the pain and anxiety caused by the procedure and are greatly preferable to general anaesthetics for use in human patients and in larger animals, such as cattle, sheep and goats.
- general anaesthetics In humans the use of general anaesthetic carries increased risks and for large animals the procedure can be difficult and time consuming.
- some local anaesthetics are known to cause muscle cell death and so are typically not suitable for use with muscle transfection techniques.
- Marcain 2.5 mg/ml from Astra, bupivacain hydroclorid
- a structurally similar local anesthetic is lidocain and an alternative used in the examples below is ketaime.
- cells within the muscle are transfected with a field strength of at least about 5 V/cm.
- cells within the muscle are transfected with a field strength of at least about 10 V/cm.
- DNA encoding an antigen was administered according to the method of the invention and the muscle was stimulated with a field strength of about 10 V/cm to about 25 V/cm.
- a large increase in antibodies against the antigen were detected for low voltage stimulation as compared to injected naked DNA.
- boost injection is likely to enhance the immune response further.
- This can be done with electroporation or with other immunization strategies and may comprise the injection of an antigen, of DNA or of both.
- animals have been immunized with plasmid DNA and then later with a certain virus encoding the same antigen in order to obtain a further increase in the cellular immune response. See, e.g., Schneider et al . ,
- boost injection may be given soon after the initial immunization (i.e., within a few days or a week) .
- booster immunizations may be given many years after the first injection.
- boost injections are given at a time from about two weeks to about four months after the initial immunization.
- boost injections are given at a time from about one month to about two months after the initial immunization.
- non-muscle cells that are later found in lymph nodes or spleen; third it seems to enhance the muscle cells ' /ability to present antigen (MHC class I staining) ; fourth, electrical stimulation will cause muscle activity that is likely to increase the lymph flow from the muscles (e.g. low voltage stimulation) .
- the mechanism is probably due to many of these factors in combination and the contribution of each one of them will depend on the type of immune response being induced. This may be controlled by use of an appropriate embodiment of the invention.
- electroporation of cells at the injection site of a molecule in skeletal muscle is effective even at surprisingly low field strengths of 5 to 25 V/cm, e.g.
- the invention provides a method of delivering a molecule to cells residing within the skeletal muscle of a mammal in vivo comprising: injecting the molecule into an injection site in the skeletal muscle of the mammal; positioning electrodes near the injection site, such that current travelling through the electrodes passes through the injection site; and electrically stimulating the muscle with an electrical current having a field strength of at least 5 and less than 25 V/cm.
- a method of genetically immunizing a mammal comprising: injecting DNA encoding an antigen into an injection site in a skeletal muscle of the mammal; positioning electrodes near the injection site such that current travelling through the electrodes passes through the injection site; and electrically stimulating the muscle with an electrical current having a field strength of less than about 100 V/cm.
- the invention also provides a method of delivering a molecule to cells residing within the skeletal muscle of a mammal in vivo comprising: injecting the molecule into an injection site in the skeletal muscle of the mammal; positioning electrodes near the injection site, such that current travelling through the electrodes passes through the injection site; and electrically stimulating the muscle with an electrical current having a field strength of from about
- Wistar rat muscles were injected with DNA plasmid containing the f3-galactosidase gene containing a 100:1 molar excess of large T-antigen nuclear localization signal . This has been shown in other transfection studies to improve the transfection. See, Collas et al . Transgenic Res . 6:45 1-8 (1996) .
- the muscle were stimulated with 10 trains of 100 pulses of 50-p.s duration.
- the muscles containing the large T-antigen nuclear localization signal had the highest number of transfected fibers. Specifically, the muscle co- transfected with large T-antigen nuclear localization signal had 100 and 38 transfected fibers versus 7.3 and
- Example 2 Genetic Immunization of Rabbits: A female rabbit (4.5 kg) was injected into the right femuralis rectus with 2 milliliters of 1 ⁇ g/ ⁇ l of DNA plasmid containing the rat neural agrin cDNA driven by the CMV promotor (Cohen et al . MCN, 9, 237-53 (1997) ) . The first milliliter was injected equally in ten places superficial in the muscle followed by 10 trains of 1000 pulses delivered at a frequency of 1000 Hz. The second milliliter was placed further down in the muscle. To test the rabbit serum, rat muscles and COS cells were transfected with the same construct. Muscles were taken out 5 days after transfection and the COS cells were stained 4 days after transfection.
- Bleeds were collected at days 0, 19, 50, 81 and 106 and diluted 1:100 and 1:1000. After 19 days the bleed contained enough antibody in the serum to give a weak staining of transfected fibers when diluted 1:10. As a positive control the monoclonal antibody (mAb) AG-86 was used. See Hoch et al . EMBOJ, 12 (13): 2814-21(1994). Preimmune serum did not show any staining of transfected fibers. Later bleeds all had agrin antibodies in the serum. Bleed collected at day 50 or later contained sufficient antibodies to stain sections at a dilution of 1:1000.
- FIG. 3a illustrates the agrin transfected COS cells stained with antiserum from immunized rabbit (diluted 1:100) and fluorescein conjugated secondary antibody.
- COS cells were stained by first fixing the cells in 1.5% paraformaldehyde for 10 minutes, followed by a 30 minute wash with phosphate buffered saline (PBS). The cells were then blocked with 0.2% bovine serum albumin, triton X-100, 0.1% in PBS 0.1M, for 4 minutes . Serum diluted in the same solution was added to the cells and allowed to incubate for 20 minutes. Cells were washed for 4 minutes in PBS and incubated with the secondary antibody (Cappel, 55646) for 10 minutes followed by a PBS wash.
- Mouse primary mAb Agr- 86 was included in the same antibody mixture and rhodamin conjugated secondary antibody (Sigma T-5393,
- Figure 3b illustrates the same cells stained with mAb Ag- 86/rhodamin conjugate.
- DH- CNTF an agonistic variant of human ciliary neurotrophic factor (Saggio et al . EMIBO J. 14, 3045-3054, 1995); AADH-CNTF, an antagonistic variant of human ciliary neurotrophic factor (Di Marco et al . Proc. Natl. Acad. Sci.
- sec-DHCNTF a secreted form of DH-CNTF.
- the muscles were either not electrically stimulated or stimulated immediately after DNA injection using 30 trains of 100 or 1000 square bipolar pulses (duration 200 microseconds; amplitude setting 150 V, effective voltage ⁇ 25 V) each, delivered at a frequency of 1000 Hz with a two second interval between successive trains .
- mice Groups of two-month old male CD1 mice were inoculated bilaterally in the quadriceps muscles with 100 micrograms (2 x 50 microliters of a 1 mg/ml solution of DNA in saline) of sec-DHCNTF plasmid, with or without electrical stimulation of the muscle immediately after DNA injection.
- Stimulation conditions were 10 trains of 1000 square bipolar pulses (amplitude setting 150 V) delivered at a frequency of 1000 Hz with a two second interval between successive trains.
- Both of the mycobacteria secreted proteins MPB70 and 85B were isolated and purified from culture fluid of Mycobacterium bovis BCG Tokyo and BCG Chopenhagen respectively, growing on Sauton media. PBS pH 7.4 was used to resuspend freeze-dried aliquots of the purified proteins to appropriate concentration for immunization or ELISA plate coating.
- CMV70 which is the M. bovis MPB70 protein encoding sequence inserted into the pcDNA3
- CMV promoter from Hewinson et al . , Central Veterinary Laboratory, Surry, UK
- 85b which contains the mycobacterium tuberculosis gene encoding 85B without the mycobacterial signal sequence inserted into the vlJns- tPA vector from Merck.
- the bacterial gene is preceded by the promoter intron A of the first immediate early antigen IE1 of CMV (85b from K. Huygen, Pasteur Institute of Brussels, Belgum) .
- 85a expresses the mycobacterium tuberculosis gene encoding the 85A protein, and a different form of 85b that it is inserted into the VR1020 vector from VICAL (from K. Huygen, Pasteur Institute of Brussels, Belgum) . Plasmids from transfected E. Coli cultures were amplified and purified by using Genomed Jetstar purification kit, and by Aldevron DNA Purification Service to GMP standards . The purity of our DNA constructs were confirmed by enzyme digestion and agarose-EtBr electrophoresis . The concentration was measured by the 280/260 nm absorption ratio. The stock solution was stored at -20°C until needed.
- the luciferase reporter gene used in these experiments contained a CMV promoter (VR-1255 from VICAL) . /
- the assay was performed using the kit developed by Promega, with the organs in question homogenized and added to the assay buffer and purified by centrifugation. Activity was with a TD-20/20, Luminometer from Turner Designs (Sunnyvale, CA, USA) .
- mice were immunized subcutaneously with 100 ⁇ l equal amount of proteins (MPB70 or 85B) at a concentration of 1 mg/ml in PBS sonicated with Incomplete Freunds Adjuvant (Behringwerke AG, Marburg, Germany) .
- Mycobacterium bovis BCG (Moreau) was harvested from cultures grown in Satoun medium and washed twice with PBS buffer. The spun-down bacteria were homogenized carefully with PBS to an approximate concentration of 200 mg/ml. 100 ⁇ l of this suspension was injected subcutaneously into the mice .
- DNA injections and immunization with electrical stimulation were given with a 28-gauge insulin needle to deliver 0.5 - 50 ⁇ g of plasmid DNA in 50 ⁇ of physiological saline to quadriceps in mice bilaterally (final concentration of DNA was 0.01, 0.1, or 1 ⁇ g/ ⁇ l, for a total of 1, 10 or 100 ⁇ g DNA per mouse) .
- electrodes were placed on the /skin to deliver an electric field at the site of DNA delivery.
- the electroporation was given as 8 trains of 1000 pulses delivered at a frequency of 1000 Hz. Each pulse lasted for 200 ⁇ s positive and 200 ⁇ s negative for a total pulse duration of total 400 ⁇ s .
- the electrical field strength varied with the change in resistance in the tissue of each animal, but the field strength was in the range of approximately 25-35 V over approximately 2.5 - 3 mm, or from about 83 V/cm to about 140 V/cm.
- Each train was delivered at two second intervals, with each train lasting one second.
- Venous blood was taken from the mice after four and eight weeks. Samples were left over night at 4 °C spun down and stored aliquoted at -20°C.
- ELISA ELISA were performed in Costar high-bind microtiter plates coated with native protein (85B or MPB70) 100 ⁇ l per well, 5 ⁇ g/ ⁇ l in PBS with sodium azide (stable for months) . Plates were stored at least over night at 4°C before use. Before use and between every step, the plates were washed 3 times with PBS + 0.1 % Tween 20. All incubations were performed at 37°C for one hour, except the last developing step, which was performed at room temperature for 10 minutes. The assay steps were as follows :
- a positive control standard included in each ELISA microtiterplate was set to 1.0 (divided by itself) . All other values obtained were divided by the positive control value, to be able to compare OD values from different microtiter plates within the same and different experiments.
- B6D2 mice were selected for the experiment and divided into three groups .
- One group received DNA plasmid and electrical stimulation (EP) .
- the second group received only DNA.
- the third group consisted of control animals, which received only saline and electrical stimulation.
- each of the groups that received DNA were divided into subgroups according of the dose and type of DNA injected.
- the total DNA dose used in the mice was either 100, 10 or 1.0 ⁇ g in 100 ⁇ l saline (50 ⁇ l in each muscle) .
- the symbols refer to different doses of DNA, with each symbol representing the mean titer from a group of mice (5-7 animals) .
- Large symbols represent antibody titer from animals receiving 100 ⁇ g DNA; medium-size symbols, 10 ⁇ g DNA; and small symbols, 1 ⁇ g DNA.
- Circles represents EP-treated animals and diamonds no EP . Filled squares are from animals immunized with protein in IFA and plain lines (no symbols) are from animals immunized with BCG bacila.
- Serum samples were tested by an ELISA assay designed for subtyping of antigen (MPB70 or 85B) specific immunoglobulins .
- the average antibody titer is shown for each group of animals as a function of optical density at 405 nm with serial dilution of serum samples collected at 4 and 8 weeks.
- the overall pattern is that EP-treated animals react with a significantly higher titer of immunoglobulins to the antigen encoded by the injected plasmid for the three subclasses of immunoglobulin tested.
- Thl cellular immune response is indicated by elevated serum concentration of antigen- specific immunoglobulins of subclass 2a.
- a humoral Th2 immune response is characterized by increasing antigen- specific IgGl and IgG2b antibodies in serum.
- Serum samples from DNA-EP immunized mice contained elevated levels of IgGl, IgG2a and IgG2b ( Figure 5) . This indicates that the animals react with both humoral and cellular immune responses.
- mice that have been immunized with M bovis BCG or protein-WA our mice seem to have lower titers of IgGl and IgG2b, but at the same or higher level with regard to IgG2a.
- the M tuberculosis-specific secreted/membrane protein MPB70 tends to elicit a weaker immune response than the widely cross-reacting common mycobacterial antigen 85B.
- 85b DNA all three doses of plasmid with EP give a high immunoglobulin response for the three antibody subclasses tested.
- mpb 70 DNA only the two highest doses of plasmid injected give a high immunoglobulin response.
- Animals that receive more than 1 ⁇ g 85b have almost the same antibody titer as an animal that were given 100 ⁇ g.
- the response required a greater dose of DNA.
- Muscle cells normally do not express either MHC class I or II at a detectable level.
- MHC I and II mouse anti MHC class I from Pharmingen clone 34-2-12S, mouse anti MHC class II clone 25-29-17, both were directly conjugated with FITC
- MHC class I we find that neither muscle cells nor other cells in the area express MHC I after injection of saline followed by EP. With injection only of plasmid (no EP) , the cells in muscle fasciae start to express MHC I at a detectable level.
- MHC class II was detected in the fasciae and in- between muscle fibers only after plasmid injection followed by EP. HAS-staining shows that mononucleated cells are recruited to the area after DNA injection and EP treatment. The area in which we find MHC class II positive cells seems to be co-localized to that in which we find mononucleated cells after HAS staining. Without being bound by any particular theory, this co- localization may result from a combination of two factors. First, EP may cause local damage to the muscle. Second, the expression of a foreign antigen encoded by the injected plasmid functions as a strong signal for recruitment of immune cells.
- Three rats were intramuscularly injected in the soleus muscle, surgically exposed, with 25 ⁇ g Luc cDNA dissolved in 50 ⁇ l of 150 mM sodium phosphate buffer pH 7.2. Following the injection, electrodes were inserted into the muscle near the site of the injection in two of the rats, and electroporation given. The third rat received no electrical stimulation.
- the spleens of the three rats were removed and analyzed for luciferase activity. As shown in Table 1, the luciferase activity in the spleens of the rats that received electrical stimulation was more than ten times greater than the activity in the spleen of a rat that did not receive electrical stimulation. These results indicate that transfection of immune cells residing in muscle is increased by electroporation.
- mice were intramuscularly injected into the quadriceps with 50 ⁇ g of Luc plasmid DNA dissolved in 50 ⁇ l of 150 mM sodium phosphate buffer pH 7.2. In six of the eleven mice, the injection was followed by electroporation .
- the lymph nodes of the mice were removed and analyzed for luciferase activity. As shown in Figure 6, the luciferase activity in the lymph nodes of the mice that received electroporation exhibited significantly greater luciferase activity that in the mice that did not receive electroporation. These results indicate that electrical stimulation increases the transfection of immune cells residing in the muscle.
- the lymph nodes of the rats were removed and analyzed for luciferase activity.
- the luciferase activity in the lymph nodes draining the right-side muscles that received electroporation was substantially higher than the activity of the lymph nodes draining the muscles on the left side that did not receive electroporation.
- mice Thirty-four mice were separated into groups of five to seven mice. Each mouse was intramuscularly injected in the quadriceps as follows. Group 1, saline +EP; group 2, mpb70 no EP; group 3 mpb70 and EP; group 4 mpb70 + Marcain but no EP; group 5 mpb70 Marcain and EP . Final concentration in the solution containing DNA was 1 ⁇ g/ ⁇ l dissolved in 0.9% NaCl and group 4 & 5 also received 2.5 mg/ml Marcain in the DNA solution. Both muscles in each animal were injected with 50 ⁇ l of one of these solutions.
- the electrical stimulation was delivered shortly after injection to the muscles of selected mice and given near the site of injection.
- the sera were collected from the mice at four and eight weeks .
- a boost injection 50 ⁇ g of mpb70
- a final ELISA was done on serum collected after 9 weeks . Referring to Figures 8-10, ELISA analysis of the sera revealed no significant differences between the genetically stimulated immune response in the animals that received /Marcain and those that did not . Similar results are obtained with the 85B construct. These results were unexpected because Marcain is known to kill muscle cells.
- mice were divided into two groups : group 1 consisted of five mice, group 2 had six mice. Each mouse was injected with 50 ⁇ l with 25 ⁇ g CMV Luc plasmid DNA dissolved in 0.9% NaCl in each left quadriseps muscle. The right muscle received the same amount of DNA but mixed with Marcain to a final concentration of 0.5 ⁇ g/ ⁇ l DNA and 2.5 mg/ml Marcain. All muscles in mice in group 1 were not electroporated. All muscles in group 2 received electroporation.
- mice Six groups of mice were selected for use in the following protocol . Initial immunizations took place on day 0. Each mouse in the first group received an intramuscular injection of a saline solution followed by electroporation. A second group of three mice received an injection of 25 ⁇ g 85B protein and electroporation. Another group of three mice were injected with 25 ⁇ g 85B protein without electroporation. A group of five mice received 100 ⁇ g of 85b DNA in solution without electroporation. Another group of five mice received 10 ⁇ g of 85b DNA and electroporation. Finally, a third group of five mice received 100 ⁇ g of 85b DNA and electroporation .
- DNA without electrical stimulation did not have much effect compared to saline. Both doses of DNA with electrical stimulation had an effect, shown by the low luciferase activity. Without being bound by any particular theory, it appears that transfection at day 0 with electroporation caused a cellular immune response that was rapidly mobilized and killed 85B/Luc-expressing fibers five days after the boost injection at week 8.
- mice Eight weeks after the initial immunization, the animals were given a booster injection with DNA (35 ⁇ g in 50 ⁇ l 0.9 % NaCl) encoding for the corresponding protein antigen given in the first injection.
- the control group was split in two: four mice received mpb70 (group NaCl + mpb 70) and the other four received 85b group (NaCl ⁇ 85b) .
- the subsequent antibody response was measured five weeks later with ELISA. If the humoral response was stimulated/primed by the protein injection, one would expect to see a stronger increase in IgGl antibodies after immunization with DNA.
- an elevated level of IgGl was detected in the mice that received the initial protein, either 85B or MPB70 vaccination indicating that a humoral response was induced in these mice compared with mice that only received DNA.
- the ELISA was also done on serum from animals immunized with a different construct, hence the 85B ELISA was done on serum from animals that were previously immunized with the mpb70 plasmid (to serve as a negative control) . No cross-reaction was observed.
- mice Four groups of mice were selected for the following protocol. Each mouse was intramuscularly injected in the quadriceps as follows. The first group of six mice were injected with 0.9% saline and exposed to electroporation. Another group of six mice were injected with 100 ⁇ g mpb70 plasmid DNA dissolved in 0.9% NaCl and received no electroporation. A third group consisting of seven mice were injected with 100 ⁇ g mpb70 plasmid DNA dissolved in 0.9% NaCl and received electroporation at standard field strengths. A final group of seven mice were injected with 100 ⁇ g mpb70 plasmid DNA dissolved in 0.9% NaCl and received electroporation at lower field strengths.
- the electrical stimulation was delivered shortly after injection and given near the site of injection.
- Each mouse was electrically stimulated with 8 trains of 1000 pulses at 1000 Hz. Each pulse lasted for 200 ⁇ s positive and 200 ⁇ s negative for a total pulse duration of total 400 ⁇ s .
- the electrical field strength varied with the change in resistance in the tissue of each animal, but the field strength for the standard voltage level was in the range of approximately 50-70 V over approximately 3-4 mm, or from about 125 to about 233 V/cm.
- the electric field strength was from about 10 V/cm to about 25 V/cm at the low voltage electroporation. This low voltage stimulation caused strong muscle contraction.
- Each train was delivered at two second intervals with each train lasting one second.
- Figure 14 shows the results of the eight week ELISA. The results were similar at four weeks, but are not shown. This experiment was also done with a different antigen 85B with similar results. The eight week results show that low voltage stimulation enhances immune response compared to naked DNA injection. This enhanced immune response could be due to the induced muscle activity or by transfecting cells other than muscle cells such as immune cells residing within the muscle.
- mice Twelve Balb/C mice were separated into four groups . Three mice received 85a and EP, three received 85a without EP, three mice received a plasmid encoding ⁇ - galactosidase ( ⁇ -gal , see previous Examples for details about construct) with EP, and three mice received ⁇ -gal without EP. Fourteen days later the spleens were removed from the animals. Cells were isolated and treated according to standard ELISPOT procedures . See Schneider et al, Na ture Medicine 4:397-402 (1998).
- the peptides used to stimulate spleenocytes from 85a immunized animals were: P-ll, an epitope from 85A that specifically binds to MHC class I and thereby stimulates CD8 positive cells ( Figure 15 A) ; P-15, an epitope from 85A that specifically binds to MHC class II and thereby stimulates CD4 positive cells ( Figure 15 B) . See Denis et al . , Infect . Immun . 66:1527-1533 (1998) for details about the peptides.
- the peptide used to stimulate spleenocytes from ⁇ - Gal immunized animals were AA 876-884 from E. Coli beta- galactosidase, this peptide specifically binds to MHC class I and thereby stimulates CDS-positive cells. See Figure 15 C.
- Results shown in Figure 15 demonstrate an increased number of both CD4 and CD8 positive T-cells when immunization is done in combination with EP. Hence, the cellular branch of the immune system is stimulated.
- CD8- and CD -positive T-cells are often associated with good protection against many serious infectious diseases in vaccinated humans. It is also believed to be important in protection and the treatment of cancer.
- Antibodies were used to stain cells expressing S- 100 (Z0311, rabbit IgG, DAKO, Denmark) and vimentin (V6630, mouse IgG, Sigma-Aldrich, St. Louis, MO) .
- Muscle bundles were permeablized with chilled methanol for 10 minutes at -20°C, followed by washing 3 times in PBS and 30 minutes incubation with 0.2% bovine albumin (A-7906, Sigma-Aldrich) for Z0311 and 5% goat serum for V6630.
- the primary antibody were diluted 1:400 in a PBS solution containing 0.2% bovine albumin for Z0311 and 5% goat serum for V6630, 0.3% Triton X-100 and 0.1% NaAzide. After incubation of muscle bundles for 1 hr at RT with the primary antibody the bundles were washed 3 times with PBS.
- the bundles stained with Z0311 were then treated with the goat Cy3 conjugated anti-rabbit secondary antibody (1:500 in PBS, 111-166-003, Jackson
- Example 17 - Vaccination applied in large animals Goats were immunized with DNA as follows: xylazin was given (intra muscularly) as sedative and analgesic (0.2 mg/kg), and further the goats were given ketamine (5 mg/kg body weight) or lidocain (50 mg) as anaesthetic intra muscularly about 5-15 minutes before treatment. The animals were left in their stable until steady sleep. After /D A injection with electroporation, the goats were given the anti-sedative atipamezol (0.05mg/kg body weight) ( 2 -antagonist) to avoid stomach trouble.
- DNA was given as two injections of 100 ⁇ l DNA solution (a mixture of mpb70 and 85b both in the concentration of 0.5 ⁇ g/ ⁇ l saline) intra muscularly in the right Gastroc nemicus (medial-lateral) . Blood samples were taken every fortnight and assayed by ELISA (see example 4) .
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01928065A EP1280550A2 (en) | 1997-04-03 | 2001-05-04 | Electroporation for introduction of molecules into cells |
AU54932/01A AU5493201A (en) | 1997-04-03 | 2001-05-04 | Method for introduction of molecules into cells |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4259497P | 1997-04-03 | 1997-04-03 | |
US09/055,084 US6110161A (en) | 1997-04-03 | 1998-04-03 | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
US09/565,140 US6261281B1 (en) | 1997-04-03 | 2000-05-05 | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US09/565,140 | 2000-05-05 | ||
US09/899,561 US20020038112A1 (en) | 1997-04-03 | 2001-07-05 | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US10/141,561 US6610044B2 (en) | 1997-04-03 | 2002-05-07 | Method for genetic immunization |
US10/620,271 US6958060B2 (en) | 1997-04-03 | 2003-07-14 | Method for muscle delivery of drugs, nucleic acids and other compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001085202A2 true WO2001085202A2 (en) | 2001-11-15 |
WO2001085202A3 WO2001085202A3 (en) | 2002-03-28 |
Family
ID=35910568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/001970 WO2001085202A2 (en) | 1997-04-03 | 2001-05-04 | Electroporation for introduction of molecules into cells |
Country Status (4)
Country | Link |
---|---|
US (6) | US6261281B1 (en) |
EP (1) | EP1280550A2 (en) |
AU (1) | AU5493201A (en) |
WO (1) | WO2001085202A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063555A2 (en) | 2006-11-17 | 2008-05-29 | Genetronics, Inc. | Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
Families Citing this family (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
US20040052773A1 (en) * | 2002-01-18 | 2004-03-18 | Inovio As | Production of multi-chain protein from muscle |
AU2003219805B2 (en) * | 2002-02-15 | 2009-06-04 | Eisai Inc. | Electroporation methods for introducing bioactive agents into cells |
US8209006B2 (en) * | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US8175711B2 (en) | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
EP1545432A4 (en) * | 2002-09-26 | 2007-03-14 | Pfizer Prod Inc | Use of excipients to increase dna uptake by swine muscle cells |
US20060247190A1 (en) | 2002-10-21 | 2006-11-02 | Kathleen Beach | Compositions and methods for treating human papillomavirus mediated disease |
US20050287118A1 (en) * | 2003-11-26 | 2005-12-29 | Epitomics, Inc. | Bacterial plasmid with immunological adjuvant function and uses thereof |
US20050277127A1 (en) * | 2003-11-26 | 2005-12-15 | Epitomics, Inc. | High-throughput method of DNA immunogen preparation and immunization |
US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
US7541185B2 (en) * | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
DK1709159T3 (en) | 2003-12-23 | 2019-07-29 | Viacyte Inc | DEFINITIVE ENDODERM |
WO2007059007A2 (en) | 2005-11-14 | 2007-05-24 | Cythera, Inc. | Markers of definitive endoderm |
CN109628371B (en) * | 2003-12-23 | 2021-02-19 | 维亚希特公司 | Definitive endoderm |
US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
US7625753B2 (en) * | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
EP2377922B1 (en) | 2004-04-27 | 2020-04-08 | Viacyte, Inc. | PDX1 expressing endoderm |
FR2872055B1 (en) | 2004-06-24 | 2008-02-08 | Yves Leon Scherman | DEVICE FOR TRANSFERRING MOLECULES TO CELLS USING A FORCE OF PHYSICAL ORIGIN AND COMBINATION FOR IMPLEMENTING THE METHOD |
CA2966883A1 (en) | 2004-07-09 | 2006-02-16 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
CA2576872C (en) * | 2004-08-13 | 2013-11-12 | University Of Georgia Research Foundation, Inc. | Compositions and methods for self-renewal and differentiation in human embryonic stem cells |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
US20070048289A1 (en) * | 2005-08-31 | 2007-03-01 | Grandjean Pierre A | Cellular intervention to treat damaged myocardium |
ES2743202T3 (en) | 2005-10-27 | 2020-02-18 | Viacyte Inc | Endoderm of the dorsal and ventral proximal intestine expressing PDX1 |
US20070253969A1 (en) * | 2005-11-14 | 2007-11-01 | Freda Stevenson | Materials and methods relating to DNA vaccination |
US7695965B2 (en) * | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
AU2007224116B2 (en) * | 2006-03-02 | 2013-11-07 | Viacyte, Inc. | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
US8260411B1 (en) | 2006-09-06 | 2012-09-04 | Twin Star Medical, Inc. | Conductive injection and aspiration device and method |
WO2008048647A1 (en) * | 2006-10-17 | 2008-04-24 | Cythera, Inc. | Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells |
EP2094086B1 (en) * | 2006-11-08 | 2013-08-28 | Veritas Bio, LLC | In vivo delivery of double stranded rna to a target cell |
US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
PT2222697E (en) | 2007-11-01 | 2013-02-15 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
AU2009231559B2 (en) * | 2008-04-04 | 2015-10-22 | The Trustees Of The University Of Pennsylvania | Consensus sequences of Chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
WO2009124309A2 (en) * | 2008-04-04 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same |
CA3229301A1 (en) | 2008-11-14 | 2010-05-20 | Viacyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
WO2010086743A2 (en) | 2009-02-02 | 2010-08-05 | Chrontech Pharma Ab | Compositions and methods that enhance an immune response |
US20100298697A1 (en) * | 2009-05-19 | 2010-11-25 | Medtronic, Inc. | Method and devices for improved efficiency of rna delivery to cells |
US8207138B2 (en) | 2009-05-19 | 2012-06-26 | Medtronic, Inc. | Methods and devices for improved efficiency of RNA delivery to cells |
CN102821790A (en) | 2009-09-14 | 2012-12-12 | 宾夕法尼亚大学托管会 | Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
CN106987595B (en) | 2009-11-02 | 2021-07-06 | 宾夕法尼亚大学托管会 | Foot and Mouth Disease Virus (FMDV) consensus proteins, their coding sequences and vaccines prepared therefrom |
CA2784488A1 (en) | 2009-12-16 | 2011-06-23 | Chrontech Pharma Ab | Injection needle and device |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
EP2539354B1 (en) | 2010-02-08 | 2017-04-05 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2621540A4 (en) | 2010-09-27 | 2014-08-27 | Univ Pennsylvania | Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria |
PL3590949T3 (en) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof |
CN107007348B (en) | 2010-10-25 | 2019-05-31 | 美敦力Af卢森堡有限责任公司 | For the estimation of nerve modulation treatment and device, the system and method for feedback |
KR102364214B1 (en) | 2010-11-12 | 2022-02-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same |
KR20140007404A (en) | 2011-01-31 | 2014-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
EP3760227A1 (en) | 2011-02-11 | 2021-01-06 | The Trustees of the University of Pennsylvania | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CN103717249B (en) | 2011-06-15 | 2017-03-22 | 克洛恩泰克制药股份公司 | Injection needle and device |
US9446114B2 (en) | 2011-07-11 | 2016-09-20 | Inovio Pharmaceuticals, Inc. | Cross-protective arenavirus vaccines and their method of use |
CN104203287B (en) | 2011-07-12 | 2017-07-14 | 费城健康及教育公司,d/b/a,德雷克塞尔大学医学院 | New difficile dna vaccine |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2848410A1 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
WO2013044225A1 (en) | 2011-09-22 | 2013-03-28 | The Trustees Of The University Of Pennsylvania | A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens |
RS62993B1 (en) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
CA2858893A1 (en) | 2011-12-12 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same |
CA2858884A1 (en) | 2011-12-12 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections |
EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9714278B2 (en) | 2012-02-22 | 2017-07-25 | The Trustees Of The University Of Pennsylvania | Use of ICOS-based CARs to enhance antitumor activity and CAR persistence |
IN2014DN06522A (en) | 2012-02-22 | 2015-06-12 | Univ Pennsylvania | |
RU2644933C2 (en) | 2012-03-08 | 2018-02-14 | Медтроник Аф Люксембург Сарл | Biomarker samples selection as part of devices for neuromodulation and relevant systems and methods |
AU2013230781B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
JP2015513914A (en) | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | Modified polynucleotides for the production of secreted proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP2836505B1 (en) | 2012-04-10 | 2019-01-23 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same |
EP2836230B1 (en) | 2012-04-12 | 2022-09-07 | The Trustees Of The University Of Pennsylvania | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
US9765156B2 (en) | 2012-07-13 | 2017-09-19 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
AR092745A1 (en) | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | COMPOSITIONS THAT INCLUDE AN ANTI-FAP UNION DOMAIN AND METHODS TO MAKE WHITE IN STROMAL CELLS FOR THE TREATMENT OF CANCER |
US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2014064534A2 (en) | 2012-10-05 | 2014-05-01 | Chrontech Pharma Ab | Injection needle, device, immunogenic compositions and method of use |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
SI2922554T1 (en) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminally modified rna |
MX364732B (en) | 2012-12-13 | 2019-05-06 | Univ Pennsylvania | Wt1 vaccine. |
KR20150130284A (en) | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cancer vaccines and methods of treatment using the same |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
MX2015011487A (en) | 2013-03-15 | 2016-02-03 | Univ Pennsylvania | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom. |
US20160324954A1 (en) | 2013-05-15 | 2016-11-10 | Chrontech Pharma Ab | Immunogenic compositions for inhibiting hepatitis d virus |
JP6692294B2 (en) | 2013-07-31 | 2020-05-13 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーBioVentures, LLC | Compositions and methods for treating and preventing cancer by targeting tumor-associated sugar chain antigens |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3080159A4 (en) | 2013-12-13 | 2017-08-02 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
CA2966035A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods of stimulating and expanding t cells |
JP7268958B2 (en) | 2014-12-01 | 2023-05-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | DNA antibody constructs and methods of use thereof |
WO2016122738A1 (en) | 2015-01-31 | 2016-08-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell delivery of therapeutic molecules |
CA3155251A1 (en) | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
WO2017015463A2 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
CN108348551A (en) | 2015-08-28 | 2018-07-31 | 宾夕法尼亚大学董事会 | Express the method and composition of the cell of signal transduction molecule in chimeric cell |
WO2017055522A1 (en) | 2015-09-29 | 2017-04-06 | Academisch Medisch Centrum | Stabilized env proteins of hiv |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
JP2018531290A (en) | 2015-10-22 | 2018-10-25 | モデルナティーエックス, インコーポレイテッド | Sexually transmitted disease vaccine |
MX2018004915A (en) | 2015-10-22 | 2019-04-01 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv). |
US11007255B2 (en) | 2016-02-05 | 2021-05-18 | Inovio Pharmaceuticals, Inc. | Cancer vaccines and methods of treatment using the same |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
MX2018012376A (en) | 2016-04-13 | 2019-08-01 | Synthetic Genomics Inc | Recombinant arterivirus replicon systems and uses thereof. |
US10233419B2 (en) | 2016-06-30 | 2019-03-19 | Zymergen Inc. | Apparatuses and methods for electroporation |
JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
JP7382230B2 (en) | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | Recombinant viral replicon system and its use |
CN110167587A (en) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | Influenza vaccines |
WO2018106615A2 (en) | 2016-12-05 | 2018-06-14 | Synthetic Genomics, Inc. | Compositions and methods for enhancing gene expression |
EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
US11344618B2 (en) | 2017-08-26 | 2022-05-31 | Academisch Medisch Centrum | HIV envelope glycoprotein immunogens |
EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Zika virus rna vaccines |
BR112020010542A2 (en) | 2017-12-13 | 2020-12-01 | Inovio Pharmaceuticals, Inc. | nucleic acid molecules, vector, composition, proteins, uses of the above, and vaccines |
CA3083528C (en) | 2017-12-13 | 2023-09-12 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting mesothelin and uses thereof |
RU2021115092A (en) | 2017-12-13 | 2022-01-24 | Иновио Фармасьютикалз, Инк. | PRAME-TARGETED CANCER VACCINES AND THEIR APPLICATIONS |
EA202091517A1 (en) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | METHODS AND DEVICE FOR DELIVERY OF VACCINES AGAINST HEPATITIS B VIRUS (HBV) |
JOP20200153A1 (en) | 2017-12-19 | 2022-10-30 | Janssen Sciences Ireland Unlimited Co | Hepatitis b virus (hbv) vaccines and uses thereof |
EP3727446A1 (en) | 2017-12-19 | 2020-10-28 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
EA202091513A1 (en) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION |
US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
WO2019129851A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
BR112020014525A2 (en) | 2018-01-19 | 2020-12-08 | Janssen Pharmaceuticals, Inc. | INDUCE AND ENHANCE IMMUNE RESPONSES USING RECOMBINANT REPLICON SYSTEMS |
EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | Rsv rna vaccines |
US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
TW202042824A (en) | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-muc1 chimeric antigen receptor (car) t cell therapy |
WO2020255013A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives |
WO2020255022A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors |
WO2020254876A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
WO2020255042A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative |
TWI772823B (en) | 2019-06-18 | 2022-08-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators |
US20220305107A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
WO2020255019A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative |
WO2020255016A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
US20220241402A1 (en) | 2019-06-18 | 2022-08-04 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
EP3986460A2 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
CA3140588A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor |
WO2020255017A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
MA56520A (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | CONSTRUCTION OF RECOMBINANT INTERLEUKIN-12 AND ITS USES |
WO2020255035A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives |
US20220249647A1 (en) | 2019-06-18 | 2022-08-11 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
CN114340664A (en) | 2019-06-18 | 2022-04-12 | 爱尔兰詹森科学公司 | Combination of Hepatitis B Virus (HBV) vaccine and HBV-targeted RNAi |
WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
US20220324916A1 (en) | 2019-06-18 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Hepatitis B Virus (HBV) Vaccines and Uses Thereof |
EP3986454A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
CA3141003A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors |
AU2020297019A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis B virus (HBV) vaccines |
AU2020295807A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines |
US20230000543A1 (en) * | 2019-11-27 | 2023-01-05 | North Carolina State University | Methods for controlling treatment volumes, thermal gradients, muscle stimulation, and immune responses in pulsed electric field treatments |
CA3174103A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
US20230330211A1 (en) | 2020-03-27 | 2023-10-19 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronaviruses |
US20210322471A1 (en) | 2020-03-27 | 2021-10-21 | Dcprime B.V. | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
AU2021243864A1 (en) | 2020-03-27 | 2022-11-03 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
AU2021289600A1 (en) | 2020-06-12 | 2023-01-19 | University Of Rochester | Encoding and expression of ACE-tRNAs |
BR112022027038A2 (en) | 2020-07-08 | 2023-01-24 | Janssen Sciences Ireland Unlimited Co | RNA REPLICON VACCINES AGAINST HBV |
WO2022056490A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
JP2023547520A (en) | 2020-11-05 | 2023-11-10 | メンドゥス・ベスローテン・フェンノートシャップ | Use of tumor-independent antigens in immunotherapy |
TW202245809A (en) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | Combination therapy for treating hepatitis b virus infection |
AU2021412833A1 (en) | 2020-12-28 | 2023-07-06 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
US20220305100A1 (en) | 2021-03-12 | 2022-09-29 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
WO2023010118A1 (en) | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same |
WO2023010126A2 (en) | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Chimeric antigen receptors for treatment of cancer |
WO2023014863A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
CA3230933A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
US20230295244A1 (en) | 2021-09-29 | 2023-09-21 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronaviruses |
WO2023150753A1 (en) | 2022-02-07 | 2023-08-10 | University Of Rochester | Optimized sequences for enhanced trna expression or/and nonsense mutation suppression |
US20240002800A1 (en) | 2022-05-16 | 2024-01-04 | Mendus B.V. | Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998043702A2 (en) * | 1997-04-03 | 1998-10-08 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
WO1999001175A1 (en) * | 1997-06-30 | 1999-01-14 | Rhone-Poulenc Rorer S.A. | Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo |
WO2000045823A1 (en) * | 1999-02-08 | 2000-08-10 | Chiron Corporation | Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0239267B2 (en) | 1984-06-12 | 1990-09-04 | Intaa Noba Kk | INIONCHUNYUSHIKICHIRYOSOCHI |
US4702732A (en) * | 1984-12-24 | 1987-10-27 | Trustees Of Boston University | Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
NZ219392A (en) | 1986-02-28 | 1989-05-29 | Smithkline Beckman Corp | Production of an immortalised primary cell line |
US5389069A (en) | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
EP0398960B1 (en) | 1988-01-21 | 1995-12-06 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
US4913699A (en) * | 1988-03-14 | 1990-04-03 | Parsons James S | Disposable needleless injection system |
US5501662A (en) | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
US5304120A (en) | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
US5507724A (en) | 1992-07-01 | 1996-04-16 | Genetronics, Inc. | Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5318514A (en) | 1992-08-17 | 1994-06-07 | Btx, Inc. | Applicator for the electroporation of drugs and genes into surface cells |
US5468223A (en) | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
JP3360865B2 (en) * | 1993-03-26 | 2003-01-07 | 東海旅客鉄道株式会社 | Train speed control method and device |
FR2703253B1 (en) | 1993-03-30 | 1995-06-23 | Centre Nat Rech Scient | APPLICATOR OF ELECTRIC PULSES FOR TREATING BIOLOGICAL TISSUES. |
US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
IL108775A (en) | 1994-02-25 | 2003-09-17 | Univ Ramot | Method for efficient incorporation of molecules into cells |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5810762A (en) | 1995-04-10 | 1998-09-22 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
WO1996035130A1 (en) | 1995-05-02 | 1996-11-07 | Philips Electronics N.V. | Method of and device for magnetic resonance imaging of objects |
US5730723A (en) * | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
WO1997007826A1 (en) | 1995-08-29 | 1997-03-06 | Cbr Laboratories, Inc. | In vivo electroporation of cells |
US5944710A (en) | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
WO1998027966A2 (en) | 1996-12-23 | 1998-07-02 | Bavarian Nordic Research Institute A/S | Encapsulated cells producing antibodies |
US20020168339A1 (en) * | 1997-01-20 | 2002-11-14 | Marc Piechaczyk | Biological material for treating a mammal by antibody gene transfer and pharmaceutical composition containing same |
FR2758569B1 (en) | 1997-01-20 | 1999-04-02 | Centre Nat Rech Scient | BIOLOGICAL MATERIAL FOR THE TREATMENT OF A MAMMAL BY TRANSFERRING ANTIBODY GENE AND PHARMACEUTICAL COMPOSITION CONCERNING THE SAME |
US6261281B1 (en) * | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
IL133708A0 (en) | 1997-06-30 | 2001-04-30 | Rhone Poulence Rorer S A | Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof |
US5965925A (en) | 1997-10-22 | 1999-10-12 | Artisan Components, Inc. | Integrated circuit layout methods and layout structures |
US6009347A (en) | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
US6440944B2 (en) * | 1998-10-16 | 2002-08-27 | Genvec, Inc. | Methods of administering adenoviral vectors |
US20030018006A1 (en) | 2001-06-29 | 2003-01-23 | Academia Sinica | In vivo electroporation-mediated cytokine/immunocytokine-based antitumoral gene |
-
2000
- 2000-05-05 US US09/565,140 patent/US6261281B1/en not_active Expired - Lifetime
-
2001
- 2001-05-04 EP EP01928065A patent/EP1280550A2/en not_active Withdrawn
- 2001-05-04 WO PCT/GB2001/001970 patent/WO2001085202A2/en not_active Application Discontinuation
- 2001-05-04 AU AU54932/01A patent/AU5493201A/en not_active Abandoned
- 2001-07-05 US US09/899,561 patent/US20020038112A1/en not_active Abandoned
-
2002
- 2002-05-07 US US10/141,561 patent/US6610044B2/en not_active Expired - Lifetime
-
2003
- 2003-07-14 US US10/620,271 patent/US6958060B2/en not_active Expired - Lifetime
-
2005
- 2005-10-20 US US11/254,567 patent/US20060041219A1/en not_active Abandoned
-
2008
- 2008-02-15 US US12/070,233 patent/US7931640B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998043702A2 (en) * | 1997-04-03 | 1998-10-08 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
WO1999001175A1 (en) * | 1997-06-30 | 1999-01-14 | Rhone-Poulenc Rorer S.A. | Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo |
WO2000045823A1 (en) * | 1999-02-08 | 2000-08-10 | Chiron Corporation | Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo |
Non-Patent Citations (11)
Title |
---|
BACHY MONIQUE ET AL: "Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse." VACCINE, vol. 19, no. 13-14, 8 February 2001 (2001-02-08), pages 1688-1693, XP002183367 ISSN: 0264-410X * |
DANKO I ET AL: "PHARMACOLOGICAL ENHANCEMENT OF IN VIVO FOREIGN GENE EXPRESSION IN MUSCLE" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 1, no. 2, March 1994 (1994-03), pages 114-121, XP001030901 ISSN: 0969-7128 * |
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 20 January 1998 (1998-01-20) LE BORGNE SYLVIE ET AL: "In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen." Database accession no. PREV199800126231 XP002183372 & VIROLOGY, vol. 240, no. 2, 20 January 1998 (1998-01-20), pages 304-315, ISSN: 0042-6822 * |
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000 SELBY MARK ET AL: "Enhancement of DNA vaccine potency by electroporation in vivo." Database accession no. PREV200000467774 XP002183376 & JOURNAL OF BIOTECHNOLOGY, vol. 83, no. 1-2, 2000, pages 147-152, ISSN: 0168-1656 * |
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1999 (1999-04) MATHIESEN I: "Electropermeabilization of skeletal muscle enhances gene transfer in vivo." Database accession no. PREV199900227202 XP002183374 & GENE THERAPY, vol. 6, no. 4, April 1999 (1999-04), pages 508-514, ISSN: 0969-7128 * |
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10) SIN JEONG-IM ET AL: "DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model." Database accession no. PREV200000068151 XP002183371 & DNA AND CELL BIOLOGY, vol. 18, no. 10, October 1999 (1999-10), pages 771-779, ISSN: 1044-5498 * |
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10) ZEWERT THOMAS E ET AL: "Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway enlarging molecule." Database accession no. PREV200000412516 XP002183373 & BIOELECTROCHEMISTRY AND BIOENERGETICS, vol. 49, no. 1, October 1999 (1999-10), pages 11-20, ISSN: 0302-4598 * |
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; SMITH L C ET AL: "Advances in plasmid gene delivery and expression in skeletal muscle." retrieved from STN Database accession no. 2001206600 XP002183375 & CURR OPIN MOL THER, (2000 APR) 2 (2) 150-4. REF: 39 , * |
KADOWAKI SHIN-ETSU ET AL: "Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation." VACCINE, vol. 18, no. 25, 2000, pages 2779-2788, XP002183369 ISSN: 0264-410X * |
MENDIRATTA SANJEEV KUMAR ET AL: "Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2." CANCER RESEARCH, vol. 61, no. 3, 1 February 2001 (2001-02-01), pages 859-863, XP002183368 ISSN: 0008-5472 * |
ZUCCHELLI S ET AL: "Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer." JOURNAL OF VIROLOGY, (2000 DEC) 74 (24) 11598-607. , XP002183370 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063555A2 (en) | 2006-11-17 | 2008-05-29 | Genetronics, Inc. | Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
Also Published As
Publication number | Publication date |
---|---|
US6610044B2 (en) | 2003-08-26 |
US20040092907A1 (en) | 2004-05-13 |
EP1280550A2 (en) | 2003-02-05 |
US6958060B2 (en) | 2005-10-25 |
US20060041219A1 (en) | 2006-02-23 |
AU5493201A (en) | 2001-11-20 |
US20020038112A1 (en) | 2002-03-28 |
US20080147131A1 (en) | 2008-06-19 |
US6261281B1 (en) | 2001-07-17 |
US7931640B2 (en) | 2011-04-26 |
WO2001085202A3 (en) | 2002-03-28 |
US20030065362A1 (en) | 2003-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001085202A2 (en) | Electroporation for introduction of molecules into cells | |
US6110161A (en) | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle | |
Tollefsen et al. | Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation | |
JP2007332149A (en) | Vaccine against mycobacterial infection | |
US10206997B2 (en) | Facilitator-DNA combination vaccine | |
WO2000045823A1 (en) | Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo | |
WO2021178661A1 (en) | Compositions containing a pathogenic antigen and an immune stimulator | |
Connolly et al. | Enhancement of antigen specific humoral immune responses after delivery of a DNA plasmid based vaccine through a contact-independent helium plasma | |
JP5165567B2 (en) | Electrical introduction of nucleic acids into tissue cells | |
AU2007322075B2 (en) | Methods of enhancing immune response using electroporation-assisted vaccination and boosting | |
US20180000928A1 (en) | Immunogenicity of an Optimized Synthetic Consensus DNA Vaccine for Porcine Epidemic Diarrhea Virus | |
KR102395493B1 (en) | Hiv-1 env dna vaccine plus protein boost | |
US20240009300A1 (en) | Dna encoded nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine | |
AU2013206520B2 (en) | Methods of enhancing immune response using electroporation-assisted vaccination and boosting | |
MXPA99009026A (en) | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001928065 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001928065 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001928065 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |